Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Renal Insufficiency 1Kidney Failure, Chronic 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 28pembrolizumab 24cabozantinib 23Ipilimumab 18Specimen Handling 13Magnetic Resonance Spectroscopy 13Axitinib 12lenvatinib 10Radiosurgery 9belzutifan 8atezolizumab 6CTLA-4 Antigen 6Biopsy 6cemiplimab 5Radiotherapy 5Bevacizumab 5toripalimab 4Everolimus 4Blood Specimen Collection 4avelumab 3aldesleukin 3X-Rays 3Sunitinib 3Standard of Care 3Paclitaxel 3zimberelimab 2trastuzumab deruxtecan 2tivozanib 2spartalizumab 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Renal Cell × Kidney Transplantation × Clear all
NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡